Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
3
×
biotech
boston
boston blog main
boston top stories
clinical trials
life sciences
national blog main
archive
avapritinib
biotech ipos
blueprint medicines
cstone pharmaceuticals
deals
dyne therapeutics
eli lilly
european medicines agency
fisogatinib
flatiron health
genentech
hepatocellular carcinoma
investing
jeff albers
medical
medicine
medullary thyroid cancer
metacrine
myotonic dystrophy type 1
national top stories
non-small cell lung cancer
nonalcoholic steatohepatitis
pralsetinib
rare disease drugs
rare diseases
recalls
roche
safety
salk institute
san diego blog main
san diego top stories
What
muscle
3
×
company
drug
medicines
advisory
approval
batch
blueprint
bottles
brings
cancer
candidate
contain
currently
developing
disorders
dosage
dose
dyne
dyne’s
fda
genetic
higher
ipo
label
listed
marketing
million
muscular
notes
pact
pills
preclinical
raised
rare
recall
recalled
regulatory
relaxant
ret
Language
unset
Current search:
muscle
×
fda
×
@slashgear.com
2 years ago
Muscle relaxant pills recalled because the dose is higher than listed
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
